

## Information regarding the distribution of Xvivo Perfusion AB

**In accordance with the resolution adopted by the Extraordinary General Meeting of shareholders held on September 24, Vitrolife's transplantation business, which is run in the subsidiary Xvivo Perfusion AB ("Xvivo") and its subsidiaries, will be spun off to the shareholders through distribution of the shares in Xvivo in accordance with "Lex Asea".**

The resolution means that the Vitrolife shareholders will automatically receive one share in Xvivo for each share that they own in Vitrolife. The distribution will not result in any tax effect for present Vitrolife shareholders as long as they remain as owners of Xvivo. Allotment of the cost of acquisition for the shares will be decided by the Swedish Tax Agency and will be published on Vitrolife's and Xvivo's websites.

The last day for trade in Vitrolife shares with entitlement to distribution of shares in Xvivo is September 26. The record day is October 1. It is estimated that the Xvivo shares will have been booked in each shareholder's VPC account by October 4. Trade in Xvivo shares on NASDAQ OMX First North will begin on October 8. Before the listing Xvivo will publish a description of the company containing detailed information about the company.

More information is available on Vitrolife's and Xvivo's websites, [www.vitrolife.com/corporate](http://www.vitrolife.com/corporate) and [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

September 24, 2012  
Gothenburg, Sweden  
VITROLIFE AB (publ)  
Patrik Tigerschiöld  
Chairman of the board

### Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone +46 8 614 00 20  
Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is a global biotechnology/medical device Group that has business activities within the areas of fertility and transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com)

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on September 24, 2012 at 4:35 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.